NCT04978688View on ClinicalTrials.gov

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

September 21, 2016

Study Completion Date

September 21, 2016

Conditions
Healthy
Interventions
DRUG

Relugolix

Administered as an oral tablet once daily.

DRUG

E2/NETA

Administered as an oral tablet once daily.

Trial Locations (1)

55404

Clinical Study Site, Minneapolis

Sponsors
All Listed Sponsors
lead

Myovant Sciences GmbH

INDUSTRY

NCT04978688 - Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants | Biotech Hunter | Biotech Hunter